MedTrace Logo

The Use of GnRH Agonist Trigger in the Prevention of OHSS

NCT00349258 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2006-07-06

No results posted yet for this study

Summary

To compare the incidence of ovarian hyperstimulation syndrome (OHSS) and implantation rate between high responder patients using Gonadotropin releasing GnRH) agonist or human chorionic gonadotropin (hCG) to trigger final oocyte maturation.

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Leuprolide acetate

Sponsors & Collaborators

  • Organon

    collaborator INDUSTRY

  • University of Connecticut

    lead OTHER

Principal Investigators

  • Claudio Benadiva, MD · UConn Health

  • Lawrence Engmann, MD · UConn Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-08-31
Completion
2006-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00349258 on ClinicalTrials.gov